Licofelone

Licofelone is a dual COX/LOX inhibitor being considered as a treatment for osteoarthritis and which is under development by Merckle GmbH with partners Alfa Wassermann and Lacer.
Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-LOX may reduce the gastrointestinal toxicity associated with other non-steroidal anti-inflammatory drugs, which only inhibit COX (cyclooxygenase). Licofelone is the first drug to inhibit both. It has passed the phase III trials.

COX Inhibitors Related Products:

Celecoxib; Resveratrol; Indomethacin; Lornoxicam; Amfenac Sodium Monohydrate; S-ketoprofen; Meloxicam; Aspirin; Suprofen; Etodolac; ATB-346; FK3311; Deracoxib; Parecoxib; Piroxicam

1: Payandemehr B, Khoshneviszadeh M, Varastehmoradi B, Gholizadeh R, Bahremand T, Attar H, Bahremand A, Dehpour AR. A COX/5-LOX Inhibitor Licofelone Revealed Anticonvulsant Properties Through iNOS Diminution in Mice. Neurochem Res. 2015 Sep;40(9):1819-28. doi: 10.1007/s11064-015-1669-z. Epub 2015 Jul 28. PubMed PMID: 26216049.

2: Balansky R, Ganchev G, Iltcheva M, Nikolov M, Maestra SL, Micale RT, D'Agostini F, Steele VE, De Flora S. Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke. Curr Cancer Drug Targets. 2015;15(3):188-95. PubMed PMID: 25687474.